Abstract:Protein tyrosine phosphatase 1B (PTP1B) is an enzyme that downregulates the insulin receptor. It has been considered as one of the drug targets of diabetes, and the inhibitors for PTP1B to treat type II diabetes have received considerable attention. The study reports a discovery of a new lead compound inhibiting PTP1B. In this work, PTP1B protein was expressed, purified and crystallized to the resolution of 2.1 Angstrom in the condition of 19%similar to 21% PEG8000, 200 mmol/L Mg(Ac)(2)center dot 4H(2)O. Structural based fragment screening was then performed against 768 fragment chemical compounds. These small molecular fragments were soaked with the PTP1B crystals, and three of them were found to bind at the active site A of PTP1B in the crystals. Then 14 kinds of published molecules which bind to the second active site (site B) were chosen. With the structures of these bound fragment compounds, hundreds of moleculars were calculated by computer aided drug design. Compound 20 was selected as the target compound, and it was synthesized by 13 steps with the total yield of 1.7%. The structure of compound 20 was characterized by H-1 NMR and HRMS data. Bioassay of inhibition of PTP1B by the new compounds revealed its IC50 at (3.4 +/- 1.2) mu mol/L, which was better than that of the positive control drug-sodium vanadate. The result of measurement of glucose uptake by insulin resistant HepG2 cells showed that the new compound can improve glucose uptake and had similar effect as Pioglitazone. The acute toxicity of the new compound was tested by using zebrafish larvae at two different concentrations (50 and 500 mu mol/L). The results showed there was no significant difference in heart rate, blood flow and morphology between the experiment and control group of zebrafish. All the results above implied the new compound has a good inhibition on PTP1B and low acute toxicity. It may be a potential lead compound for further drug discovery.

Rational Design of Mitochondria-Targeted Pyruvate Dehydrogenase Kinase 1 Inhibitors with Improved Selectivity and Antiproliferative Activity.

Synthesis and Biological Evaluation of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides As Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors to Reduce the Growth of Cancer Cells

Targeting the Pyruvate Dehydrogenase Complex/pyruvate Dehydrogenase Kinase (PDC/PDK) Axis to Discover Potent PDK Inhibitors Through Structure-Based Virtual Screening and Pharmacological Evaluation.

Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors

High-throughput Screening of Novel Pyruvate Dehydrogenase Kinases Inhibitors and Biological Evaluation of Their in Vitro and in Vivo Antiproliferative Activity.

Development of Dichloroacetamide Pyrimidines As Pyruvate Dehydrogenase Kinase Inhibitors to Reduce Cancer Cell Growth: Synthesis and Biological Evaluation

Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy

Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships.

Discovery of Pyrrolopyrimidinone Derivatives As Potent Pkmyt1 Inhibitors for the Treatment of Cancer

Discovery of Novel Naphthoquinone Derivatives As Inhibitors of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase.

Synthesis, biological evaluation and structure-activity relationship of novel dichloroacetophenones targeting pyruvate dehydrogenase kinases with potent anticancer activity

Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities

Targeting the PDK/PDH Axis to Reverse Metabolic Abnormalities by Structure-Based Virtual Screening with in Vitro and in Vivo Experiments.

Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents

Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro

Development of dual inhibitors targeting pyruvate dehydrogenase kinases and human lactate dehydrogenase A: High-throughput virtual screening, synthesis and biological validation

Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors

Design, Synthesis and Biological Activity of 3-Pyrazine-2-yl-oxazolidin-2-ones As Novel, Potent and Selective Inhibitors of Mutant Isocitrate Dehydrogenase 1.